Fexagratinib targets FGF, CSF, and VEGF pathways, showing potential in MS treatment by reducing inflammation and promoting ...
The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback